Previous 10 | Next 10 |
May 4, 2020 FN Media Group Presents Financialmorningpost.com Market Commentary New York, NY – May 4, 2020 – A new medical development is sweeping the country. Some may see it as controversial – but the studies don’t lie. It’...
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announce...
CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announce...
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global study protocol complying with requirements from EMA as well as FDA – CHARLEST...
Thinly traded nano cap Aeterna Zentaris (NASDAQ: AEZS ) jumps 19% premarket on average volume on the heels of positive results from a 24-subject study, AEZS-130-P01, evaluating macimorelin as a growth hormone stimulation test in pediatric patients with child-onset growth hormon...
– Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Pediatric PK/PD profile of macimorelin proved to be in the expected range and generally compara...
Aeterna Zentaris (NASDAQ: AEZS ): Q4 GAAP EPS of -$0.05. More news on: Aeterna Zentaris Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a commercialization partner for macimorelin in Europe and...
CHARLESTON, S.C., March 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced it ha...
The following slide deck was published by Aeterna Zentaris Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...